Compare HALO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | SNN |
|---|---|---|
| Founded | 1998 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 12.3B |
| IPO Year | 2001 | 2002 |
| Metric | HALO | SNN |
|---|---|---|
| Price | $108.28 | $29.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 2 |
| Target Price | ★ $78.64 | $36.25 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 05-05-2026 | 03-16-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $151,862,000.00 | N/A |
| Revenue This Year | $28.24 | $8.58 |
| Revenue Next Year | $12.56 | $5.60 |
| P/E Ratio | ★ $34.78 | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $61.23 | $28.56 |
| 52 Week High | $108.49 | $38.79 |
| Indicator | HALO | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 77.65 | 45.05 |
| Support Level | $67.12 | $29.24 |
| Resistance Level | N/A | $31.18 |
| Average True Range (ATR) | 3.53 | 0.43 |
| MACD | 0.75 | -0.12 |
| Stochastic Oscillator | 97.08 | 51.78 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.